CalciMedica, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that CalciMedica, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($7.80M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($5.96M) | Aug 12, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($5.96M) | Nov 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($5.04M) | May 14, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($5.04M) | Aug 12, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($5.04M) | Nov 12, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($5.62M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($3.95M) | Aug 12, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($3.95M) | Nov 12, 2025 |
| Q3 | 2025 | Mar 31, 2024 | $130.0K | Nov 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | $130.0K | May 14, 2025 |
| Q2 | 2025 | Mar 31, 2024 | $130.0K | Aug 12, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($4.62M) | Nov 13, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($6.30M) | Nov 13, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($6.30M) | Aug 12, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($19.29M) | May 13, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($19.29M) | Aug 12, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($19.29M) | Nov 13, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($2.58M) | Nov 9, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($3.03M) | Aug 11, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($5.62M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($6.62M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($6.50M) | May 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($5.74M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($6.53M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($5.77M) | May 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($4.83M) | Nov 13, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($6.58M) | Aug 12, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($22.34M) | May 13, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($3.29M) | Nov 9, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($3.59M) | Aug 11, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($4.21M) | May 12, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($8.02M) | Nov 10, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($7.74M) | Aug 12, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($11.49M) | May 12, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($6.82M) | Nov 12, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($6.04M) | Aug 12, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($7.80M) | May 14, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($10.37M) | Nov 12, 2020 |